Abstract:Prostate cancer (PCa) is the second leading cause of death in men. Recently, some researches have showed that 5α-reductase inhibitors were beneficial in PCa treatment as well. In this study, a series of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives have been designed and synthesized in a more simple and convenient method. Most of the synthesized compounds displayed good 5α-reductase inhibitory activities and androgen receptor binding affinities. Their anti-proliferation activities in PC-3 and LNCaP cell lines were also evaluated and the results indicated that most of the synthesized compounds exhibited potent anti-proliferative activities. It is obvious that the androgen-dependent cell line LNCaP was much more sensitive than the androgen-independent cell line PC-3. Among all the synthesized compounds, 11d and 11k displayed the best inhibition activity with 4-fold more sensitive toward LNCaP than PC-3, which was consistent with their high affinities observed in AR binding assay. Molecular modeling studies suggested that 11k could bind to AR in a manner similar to the binding of dihydrotestosterone to AR. Compared to the finasteride, 11k showed a longer plasma half-life (4h) and a better bioavailability. Overall, based on biological activities data, compound 11d and 11k can be identified as potential dual 5α-reductase inhibitors and AR antagonists which might be of therapeutic importance for prostate cancer treatment.

Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α1A-Adrenoceptor Antagonists.

Design , Synthesis , and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives ( THPBs ) as Selective α 1 A-Adrenoceptor Antagonists

Design, Synthesis, and Biological Evaluation of Indoline and Indole Derivatives as Potent and Selective α1A-Adrenoceptor Antagonists.

Design, Synthesis, and Pharmacological Evaluation of Novel Tetrahydroprotoberberine Derivatives: Selective Inhibitors of Dopamine D1 Receptor

Synthesis, structure-activity relationship and biological evaluation of novel arylpiperzines as α1A/1D-AR subselective antagonists for BPH.

Asymmetric Total Synthesis and Identification of Tetrahydroprotoberberine Derivatives As New Antipsychotic Agents Possessing a Dopamine D1, D2 and Serotonin 5-HT1A Multi-Action Profile

Discovery of Novel Thiohydantoin Derivatives As Full Antagonists and Efficient Degraders of Androgen Receptor

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Design, Synthesis, Crystal Structure, Biological Evaluation and Molecular Docking Studies of Carbazole-Arylpiperazine Derivatives.

[Antagonistic Effect of Tetrahydroproberberine Homologues on Alpha 1-Adrenoceptor].

Study on Phenylethylamines New Compounds Against Benign Prostatic Hyperplasia

Synthesis, Biological Evaluation and Molecular Docking of 4-Amino-2h-benzo[h]chromen-2-one (ABO) Analogs Containing the Piperazine Moiety.

Rational Design, Synthesis, Biological Evaluation, Homology and Docking Studies of Coumarin Derivatives As Α1 -Adrenoceptor Antagonists.

Discovery of Pyridine Tetrahydroisoquinoline Thiohydantoin Derivatives with Low Blood-Brain Barrier Penetration As the Androgen Receptor Antagonists.

Clinical application of highly selectiveα1A-AR antagonist silodosin in benign prostatic hyperplasia

Discovery of Thiohydantoin Based Antagonists of Androgen Receptor with Efficient Degradation for the Treatment of Prostate Cancer

Biophore Development for Prostate Selective Α_1-Adrenoceptor Antagonist

Synthesis and blocking activities of a new class of α₁-adrenoceptor antagonists.

Design, Synthesis and Biological Evaluation of Novel Androst-3,5-diene-3-carboxylic Acid Derivatives As Inhibitors of 5Α-Reductase Type 1 and 2

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

Design, Synthesis and Biological Evaluation of Thiohydantoin Derivatives As Novel Anti-prostate Cancer Agents.